Figure 6.
Radiovirotherapy of prostate cancer tumors. Mice (n = 5 per group) bearing subcutaneous LNCaP xenografts received a single intratumoral (IT) or intravenous (IV) dose of 1.5 × 106 TCID50 measles virus–sodium iodide symporter (MV-NIS) or UV-inactivated MV-NIS with or without subsequent 131I administration (1 mCi/mouse injected intraperitoneally 4 days after virus administration). There was significant suppression (P < 0.05) of tumor growth in the combined IT radiovirotherapy group (a) at day 25 and in the combined IV radiovirotherapy group (b) at day 27 when the plots were censored because of deaths occurring in the control and single-agent treatment groups. Tumor volumes are expressed as the percentage relative to the values on the day of 131I injection in each group and plotted against days after MV-NIS treatment. Points indicate mean; bars, SEM. (c) Mice in the IT radiovirotherapy group had significantly longer survival compared to the single-agent MV-NIS group (P < 0.05). (d) Similarly, combined IV radiovirotherapy significantly increased survival compared to single-agent MV-NIS (P < 0.05).